Research endeavors toward Alzheimer’s disease (AD) treatment target early detection, focusing on improving cognition and slowing down disease progression. The advancements achieved are credited to the increase in understanding AD at the molecular level with the combined efforts of the clinicians, researchers, and the drug industries. Thus, several medications are proven successful in ameliorating the diseased symptoms; however, none could stop or reverse disease progression. Among these, recent developments in AD therapeutics based on the “cholinergic hypothesis” and “amyloid cascade hypothesis” hold enormous treatment potential.